A pump-prime aprotinin dose in cardiac surgery: Appraisal of its effects on the hemostatic system

被引:11
作者
Rossi, M
Storti, S
Martinelli, L
Varano, C
Marra, R
Zamparelli, R
Possati, G
Schiavello, R
机构
[1] UNIV CATTOLICA SACRO CUORE,DEPT HAEMATOL,ROME,ITALY
[2] UNIV CATTOLICA SACRO CUORE,DEPT CARDIAC SURG,ROME,ITALY
关键词
aprotinin; cardiopulmonary bypass; bleeding; fibrinolysis; transfusion;
D O I
10.1016/S1053-0770(97)90116-6
中图分类号
R614 [麻醉学];
学科分类号
100217 ;
摘要
Objectives: To examine pump-prime aprotinin action on coagulation and fibrinolysis in patients undergoing primary coronary revascularization. Design: A prospective randomized study. Setting: A university hospital. Participants: Forty-three patients were randomly assigned to either group A, 21 patients treated with 2 x 10(6) kallikrein inhibitor units (KIU) of aprotinin in the cardiopulmonary bypass (CPB) prime, or group B, 22 patients, untreated. Interventions: Patients, scheduled for elective coronary surgery, were treated with 2 x 10(6) KIU Of aprotinin in the CPB prime. Markers of coagulation and fibrinolysis were evaluated. Measurements and Main Results: Surgical times, number of reopenings, and allogeneic blood requirements were collected for each patient. Blood samples were obtained before and after surgery for assessing coagulation (prothrombin time [PT], activated partial thromboplastin time [aPTT], ethanol test, factor VII, antithrombin III [AT III], thrombin-antithrombin III complex [TAT], fragment 1.2 of prothrombin [F1.2]) and fibrinolysis (fibrin degradation products [FDP], plasmin-antiplasmin complexes [PAP], D-dimers) markers variations. In group A surgical times were faster, there were fewer reopenings (0 v 3), and fewer blood transfusions (1 patient v 4 patients). The two groups did not differ for PT, aPTT, and fibrinogen measurements. Postoperative FDP (measurable in more patients of group B at the end of the operation), PAP, and D-dimers postoperatory levels (less increased in aprotinin group) show the antifibrinolytic properties of the drug. Regarding the coagulation markers, factor VII decreased, whereas TAT and F1.2 increased, all to a lesser extent in the aprotinin group compared with the untreated patients, at the end of operation. Conclusion: Pump-prime aprotinin minimized, even if not completely inhibited, the activation of coagulation and fibrinolysis during CPB, possibly ensuring a less complicated and safer postoperative recovery. It seemed to allow the maintenance of a correct balance of hemostatic systems, avoiding the risk of thrombotic phenomena. Copyright (C) 1997 by W.B. Saunders Company.
引用
收藏
页码:835 / 839
页数:5
相关论文
共 24 条
[1]  
BLAUHUT B, 1991, J THORAC CARDIOV SUR, V101, P958
[2]   PROPHYLACTIC TREATMENT OF POSTPERFUSION BLEEDING USING EACA [J].
DELROSSI, AJ ;
CERNAIANU, AC ;
BOTROS, S ;
LEMOLE, GM ;
MOORE, R .
CHEST, 1989, 96 (01) :27-30
[3]  
FISH KJ, 1986, J THORAC CARDIOV SUR, V91, P436
[4]  
Gravlee G P, 1994, J Cardiothorac Vasc Anesth, V8, P213, DOI 10.1016/1053-0770(94)90066-3
[5]   NATURAL AND SYNTHETIC ANTIFIBRINOLYTICS IN CARDIAC-SURGERY [J].
HARDY, JF ;
DESROCHES, J .
CANADIAN JOURNAL OF ANAESTHESIA-JOURNAL CANADIEN D ANESTHESIE, 1992, 39 (04) :353-365
[6]  
HAVEL M, 1991, J THORAC CARDIOV SUR, V101, P968
[7]  
HORROW JC, 1990, J THORAC CARDIOV SUR, V99, P70
[8]   MECHANISM OF THE PRESERVING EFFECT OF APROTININ ON PLATELET-FUNCTION AND ITS USE IN CARDIAC-SURGERY [J].
HUANG, HM ;
DING, WX ;
SU, ZK ;
ZHANG, WZ .
JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 1993, 106 (01) :11-18
[10]   PLATELET PROTECTION BY APROTININ IN CARDIOPULMONARY BYPASS - ELECTRON-MICROSCOPIC STUDY [J].
LAVEE, J ;
SAVION, N ;
SMOLINSKY, A ;
GOOR, DA ;
MOHR, R .
ANNALS OF THORACIC SURGERY, 1992, 53 (03) :477-481